FindTrial
Sign In

Establishment of prediction model of selumetinib therapy in the treatment of plexiform neurofibroma based on exosomes test from liquid biopsy

Establishment of prediction model of selumetinib therapy in the treatment of plexiform neurofibroma based on exosomes test from liquid biopsy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036770
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plexiform Neurofibromatosis type 1

Interventions

Gold Standard:Clinical outcomes
Index test:Prediction&#32
model&#32
of&#32
selumetinib&#32
therapy&#32
in&#32
the&#32
treatment&#32
plexiform&#32
neurofibroma&#32
based&#32
on&#32
exosomes&#32
test&#32
from&#32
liquid&#32
biopsy

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 65 Years

Inclusion criteria

Inclusion criteria: All 32 patients who were enrolled in the phase 1 clinical trial of selumetinib in the treatment of plexiform neurofibroma.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
Exosomes;SEN, SPE, ACC, AUC of ROC, PPV, NPV;—

Countries

China

Contacts

Public ContactZhi-Chao Wang
shmuwzc@163.com+86 13816382311

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026